Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...

Denosumab use was associated with a lower risk for incident diabetes among patients with osteoporosis. Denosumab use is associated with a lower risk for diabetes among patients with osteoporosis, ...

Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

Panel A shows the changes in the levels of the bone-formation marker procollagen type 1 N-terminal propeptide (P1NP) and the levels of the bone-resorption marker C-terminal telopeptide (CTX) in each ...

Patient reported outcomes using Internet-based tablets to inform hospice care for minority and nonminority patients with cancer. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I.

Researchers conducted a retrospective cohort study using data from the TriNetX US Collaborative Network to compare the risk for incident OA in adults with osteoporosis treated with denosumab vs ...

Denosumab may reduce fracture risk, but increase cardiovascular risks in patients on dialysis. Denosumab may reduce fracture risk better than oral bisphosphonates for treatment of osteoporosis in ...

Ethnic and clinical differences in gBRCA and HRD mutated breast and ovarian cancers and their response to PARP inhibitors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

Prolia (denosumab) is a medication for osteoporosis. A healthcare professional administers Prolia via injection under the skin every 6 months. Medicare covers Prolia for beneficiaries. Since a ...